Sign in Subscribe
Cancer

Accurate Biomarkers for Vulvar Cancer Risk Identified in Dutch Study

Strategic Insights

— 1 min read

Researchers at the Amsterdam University Medical Center have found that a three-gene methylation marker panel can predict the risk of vulvar cancer in patients with high-grade vulvar intraepithelial neoplasia (VIN), a precursor to vulvar cancer. The study, published in the British Journal of Dermatology, analyzed a population-based cohort of patients diagnosed with high-grade VIN and found that the methylation marker panel was a significant prognostic factor for vulvar cancer development in patients with human papillomavirus (HPV)-associated HSIL.

Key Takeaways:

  • The three-gene methylation marker panel, including genes ZNF582, SST, and miR124-2, was identified as the only prognostic factor for vulvar cancer development in patients with HPV-associated HSIL.
  • In patients with HSIL, a positive methylation status was associated with a higher risk of vulvar cancer development, with a hazard ratio of 4.87 (95% CI 1.20-21.45).
  • The prognostic value of methylation remained present when selecting patients who did not receive radical surgical excision as their primary treatment, with a 5-year cancer risk of 7.7% in methylation-positive HSIL and 1.4% in methylation-negative HSIL (p=0.008).
  • In patients with dVIN, p53 status was the sole prognostic risk factor for progression to cancer, with a hazard ratio of 7.67 (95% CI 1.78-33.08).
  • The three-gene methylation test serves as a promising prognostic tool for cancer risk stratification in patients with vulvar HSIL, allowing for more conservative management strategies and potentially avoiding overtreatment.

Statistics:

  • 578 patients with a histopathological confirmed diagnosis of HSIL were included in the study.
  • 26/578 (4.5%) HSIL patients developed vulvar cancer within five years.
  • 21/46 (45.7%) dVIN patients developed vulvar cancer within five years.
  • The hazard ratio for vulvar cancer development in patients with a positive methylation status was 4.87 (95% CI 1.20-21.45).
  • The 5-year cancer risk in methylation-positive HSIL patients was 7.7%, compared to 1.4% in methylation-negative HSIL patients (p=0.008).
  • The hazard ratio for vulvar cancer development in patients with dVIN and a positive p53 status was 7.67 (95% CI 1.78-33.08).

Sources:

  • British Journal of Dermatology, 2025. (Wiley-Blackwell - www.wiley.com/; British Journal of Dermatology - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2133)
  • Amsterdam University Medical Center, location Vrije Universiteit Amsterdam, Pathology, De Boelelaan 1117, Amsterdam, Netherlands.

Read more